# Kyntra Bio, Inc.: Form 10-Q for the period ended Mar 31, 2024

- Company: [Kyntra Bio, Inc.](/companies/kynb.md) (CIK 921299)
- Form: 10-Q
- Filed: 2024-05-06
- Accepted by EDGAR: May 6, 2024, 20:10 ET
- Period: 2024-03-31
- Accession: 0000950170-24-053554
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/921299/000095017024053554/fgen-20240331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/921299/000095017024053554/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2024-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2024-01-01 to 2024-03-31 | $55.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2024-01-01 to 2024-03-31 | $25.8m | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2024-01-01 to 2024-03-31 | $38.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2024-01-01 to 2024-03-31 | $22.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2024-01-01 to 2024-03-31 | −$31.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2024-01-01 to 2024-03-31 | $5.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2024-01-01 to 2024-03-31 | $33.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2024-01-01 to 2024-03-31 | −$32.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2024-01-01 to 2024-03-31 | −$0.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2024-01-01 to 2024-03-31 | −$0.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2024-01-01 to 2024-03-31 | 98,982,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2024-01-01 to 2024-03-31 | −$59.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2024-01-01 to 2024-03-31 | $29.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2024-03-31 | $105.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2024-03-31 | $278.2m | us-gaap:AssetsCurrent |
| Total assets | at 2024-03-31 | $365.9m | us-gaap:Assets |
| Current liabilities | at 2024-03-31 | $196.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2024-03-31 | $552.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2024-03-31 | −$228.1m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/921299/000095017024053554/fgen-20240331.htm

Filed May 6, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-053554. Last ingested by Listed: Oct 24, 2026, 15:00 ET. No prices; not investment advice.